UK - Redx (AIM: REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, targeted therapeutics for the treatment of fibrotic disease and cancer today announces audited financial results for the year ended 30 September 2023.

Lisa Anson, Chief Executive Officer, Redx Pharma, commented: 'We are pleased to report significant progress across our pipeline of clinical and pre-clinical assets. Commencing our Phase 2a IPF clinical trial for our lead asset zelasudil, formerly RXC007, underscores our commitment to advancing our differentiated ROCK-inhibitor portfolio. During the year, we presented compelling preclinical data that demonstrate the potential of zelasudil in several other fibrotic indications that we intend to investigate further in the future. We are also pleased to confirm the submission of a CTA for our second ROCK asset, RXC008, for which we expect to commence a Phase 1 study early in 2024.

Despite the ongoing challenges in the equity markets and broader economic landscape, post-period we were pleased to secure a GBP14.1 million (GBP13.6 million net) equity financing with existing institutional investors which extends our cash runway into Q3 2024 and will allow us to deliver multiple near-term value inflection points, in line with our refined strategic focus. I would like to take this opportunity to again thank our shareholders for their ongoing support, and our employees whose dedication make our achievements possible.'

Contact:

Caitlin Pearson

Email: ir@redxpharma.com

Lisa Anson

Tel: +44 (0)1625 469 918

(C) 2023 Electronic News Publishing, source ENP Newswire